Status:

COMPLETED

Dutasteride for the Reduction of Alcohol Use in Male Drinkers

Lead Sponsor:

UConn Health

Collaborating Sponsors:

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Conditions:

Alcoholism

Alcohol Abuse

Eligibility:

MALE

18-65 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to evaluate whether dutasteride is safe and effective for reducing alcohol use in male drinkers who want to stop or reduce their drinking. The investigators hypothesize th...

Eligibility Criteria

Inclusion

  • Male outpatients age 18 to 65 years
  • Have an average weekly ethanol consumption of \>24 standard drinks
  • Be able to read English at the 8th grade or higher level and show no evidence of significant cognitive impairment
  • Be willing to nominate an individual who will know the patient's whereabouts in order to facilitate follow up during the study
  • Be willing to provide signed, informed consent to participate in the study (including a willingness to reduce drinking to non-hazardous levels)

Exclusion

  • Have a current, clinically significant physical disease or abnormality on the basis of medical history, physical examination, or routine laboratory evaluation
  • Have a serious psychiatric illness (e.g., schizophrenia, bipolar disorder, severe or psychotic major depression, organic mood or mental disorders, current eating disorder symptoms, or substantial suicide or violence risk) on the basis of history or psychiatric examination
  • Have a current diagnosis of drug dependence (other than nicotine or alcohol dependence)
  • Have a current diagnosis of alcohol dependence who on clinical examination by a physician, are deemed to be too severely alcohol dependent to permit them to participate in a placebo-controlled pilot study
  • Have a history of hypersensitivity to dutasteride
  • Current or past 4 month use of finasteride (Propecia), dutasteride (Avodart) or testosterone
  • Are currently taking psychotropics other than a single antidepressant with stable dose for at least 4 weeks or a non-benzodiazepine sleep medication
  • Are considered by the investigators to be an unsuitable candidate for receipt of an investigational drug

Key Trial Info

Start Date :

January 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2012

Estimated Enrollment :

47 Patients enrolled

Trial Details

Trial ID

NCT01262287

Start Date

January 1 2011

End Date

December 1 2012

Last Update

March 20 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Connecticut Health Center

Farmington, Connecticut, United States, 06030